Xencor, Inc Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Xencor, Inc (XNCR) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $207.60 million as of 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2018-02-28
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $207.60M.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $196.32M.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $168.20M.
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $126.64M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value as first filed |
|---|---|---|
| 2017-12-31 | $207.60M 10-K · filed 2018-02-28 | |
| 2017-09-30 | $196.32M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $168.20M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $126.64M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $99.79M 10-K · filed 2018-02-28 | $99.79M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |